Baseline Lung Damage Predicted Which MDR/RR-TB Patients Did Poorly on a Shortened All-Oral Regimen
A shortened all-oral regimen for MDR/RR-TB is only as strong as the patients selected for it. In a prospective cohort of adults with bacteriologically confirmed pulmonary disease in Lesotho, baseline sputum and chest radiographic findings separated patients who were likely to convert cultures quickly from those who were more likely to die, fail treatment, or recur after therapy ended.
The cohort included 238 participants with a median age of 41 years, an interquartile range of 31 to 56, and 29% women. HIV coinfection was common, affecting 62% of the group. Despite the high-risk clinical profile, 142 of 148 participants with positive baseline cultures, or 95.9%, converted within four months. The overall picture was encouraging, but not uniform. Twenty-seven unfavorable outcomes still occurred: 20 deaths, three treatment failures, and four recurrences.
Cavitation, Fibrosis, and Bilateral Disease Carried the Heaviest Prognostic Weight
Three radiographic patterns stood out again and again: fibrosis, cavitation, and bilateral disease. Each was associated with delayed culture conversion and lower odds of treatment success. High smear grade added a microbiologic signal of heavier bacillary burden, and it tracked in the same unfavorable direction.
The biology is straightforward even when the statistics are not. Cavities provide a protected compartment for Mycobacterium tuberculosis, a setting in which drug penetration can be uneven and bacterial persistence can continue despite therapy. Fibrosis reflects prior tissue destruction and remodeling, which can limit effective drug delivery and mark advanced disease. Bilateral involvement suggests a broader anatomic spread of infection, leaving less reserve when treatment begins. High smear grade, in turn, points to large organism burden at baseline, making rapid sterilization more difficult even with an effective regimen.
One result was especially clinically sobering. Severe fibrocavitary disease — defined as multilobar fibrosis with at least one cavity of 5 cm or larger — was negatively associated with favorable final outcomes, with an unadjusted odds ratio of 0.20 and a 95% confidence interval of 0.07 to 0.64. The adjusted odds ratio was 0.26 with a 95% confidence interval of 0.07 to 0.94. Cavitation with high smear grade also pointed in the same direction, with an unadjusted odds ratio of 0.29 and a 95% confidence interval of 0.11 to 0.78; the adjusted estimate was 0.39 with a 95% confidence interval of 0.14 to 1.14.
HIV Status Shifted Which Predictors Mattered Most
The study did not treat the cohort as clinically interchangeable. Predictive patterns differed by HIV status, which matters in a setting where advanced immunosuppression can alter both radiographic appearance and host response.
Bilateral disease was more strongly associated with unfavorable outcomes among participants without HIV. In those with HIV, fibrosis and high smear grade showed stronger associations. This split likely reflects different pathways to poor outcome: in HIV-negative patients, extensive structural lung involvement may dominate risk; in HIV-positive patients, immune dysfunction may magnify the consequences of fibrosis and high organism burden. The data do not reduce MDR/RR-TB to a single uniform disease process. They show distinct risk architectures layered onto the same diagnosis.
The lesson from the cohort is immediate at the bedside. A patient with extensive bilateral disease, especially when paired with cavitation or heavy smear positivity, enters treatment with a very different prognosis from a patient whose disease is more limited on imaging, even if both receive the same shortened oral regimen.
Culture Conversion Was Common, but Not Equal Across Risk Groups
Early microbiologic response remained common across the study population. Among those with positive baseline cultures, nearly all converted within four months. Yet the speed of conversion still separated lower-risk from higher-risk patients, and the radiographic findings helped explain why some patients lagged behind others.
Delayed culture conversion is not just a laboratory milestone. In pulmonary tuberculosis, persistent culture positivity reflects ongoing viable bacilli, ongoing inflammatory injury, and a longer period during which transmission may continue if infection control fails. It also flags the possibility that drug exposure is being asked to overcome a more entrenched anatomic reservoir. A shortened regimen can be highly effective and still leave a subset of patients with enough structural disease to blunt the usual response curve.
The cohort therefore points to a practical but selective approach: radiographs and baseline sputum results can be used together to identify patients who may need closer follow-up, more intensive monitoring, or a lower threshold for individualized management during shortened therapy.
Risk Stratification Could Reshape How Shortened Regimens Are Used
Shortened all-oral regimens have already improved tolerability and access compared with older, longer, more toxic tuberculosis treatment strategies. The value of this study lies in moving the field beyond broad efficacy toward patient-level prediction. Not every person with MDR/RR-TB carries the same probability of success on the same regimen.
Baseline sputum and chest radiographic features provided complementary information here. Sputum smear grade captured bacillary load. Imaging captured the structural consequences of infection. When these features were combined, they identified a subgroup at notably higher risk of poor outcome. In real-world programs, that combination could inform earlier escalation of surveillance, more frequent microbiologic checks, and closer follow-up after treatment ends, when recurrence still remains a concern.
The cohort was conducted in Lesotho, among adults with bacteriologically confirmed pulmonary disease, so the results are anchored in a high-burden setting where these decisions matter most. The findings also fit a broader clinical principle: tuberculosis outcomes are not determined solely by the drug regimen. They are shaped by the lung architecture the regimen must work through.
The study leaves one key operational challenge in place for tuberculosis programs. Baseline radiographic severity is easy to see, but translating it into a consistent, resource-sensitive risk-adapted pathway for shortened MDR/RR-TB treatment will require prospective implementation work.